USA flag logo/image

An Official Website of the United States Government

Novel method to create knockout rats using endonucleases and spermatagonialstem

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43GM099206
Solicitation Year:
2011
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA10-050
Small Business Information
TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
535 West Second Street Suite 10 Lexington, KY 40508
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Novel method to create knockout rats using endonucleases and spermatagonialstem
Agency: HHS
Contract: 1R43GM099206-01
Award Amount: $342,046.00
 

Abstract:

DESCRIPTION (provided by applicant): The laboratory rat is the preferred rodent model in pre-clinical drug studies and encompasses the bulk of accumulated knowledge in drug development. Their larger size facilitates procedures otherwise difficult in mice,including studies using instrumentation, blood sampling, and surgeries. Although rats are more suitable than mice for pharmacological, toxicological, physiological, and many biological assays, the absence of genetic engineering technologies suitable for use in the rat has made the mouse the preeminent rodent model. However, the recent emergence of new and more precise gene targeting techniques for the rat has resulted in significant growth in the production of genetically modified rats, which will undoubtedly expand at an exponential rate. A limiting factor in the adoption of genetically modified rats as the rodent model of choice has been the expensive, inefficient, and labor intensive manipulations required for their production, resulting in costs as highas 50,000 to 100,000 per genetically modified rat line. Consequently, it is essential to develop more viable technologies for rat genome engineering that result in more accurate, efficient, and cost-effective production of genetically modified rats. Transposagen Biopharmaceuticals, Inc. is the worldwide leader in the generation of genetically modified rat models and is uniquely positioned to facilitate advancements in this field. Precision BioSciences develops custom genome engineering enzymes based on engineered homing endonucleases. This research proposal is a collaborative effort to merge the two technologies and test the feasibility of using engineered homing endonucleases as an extremely specific and efficient method to produce genetically modified rats. In Phase I we will attempt to knockout the rat Rag1 gene in spermatagonial stem cells (SSCs) using a Rag1-specific endonuclease. These modified cells will then be used to generate knockout Rag1 mutant rats. For comparison, we will attempt to achieve the same result using conventional gene targeting methods in SSCs. The incorporation of an engineered endonuclease in SSCs should greatly streamlines the knockout rat production process, Transposagen Biopharmaceuticals and Precision BioSciences will collaborate in a large-scale Phase II project to generate precisely engineered high-value rat models. Success in this project will significantly reduce the cost of transgenic rat production and give academic and industry investigators greater access to improved rodent models. PUBLIC HEALTH RELEVANCE: The laboratory rat has been a valuable animal model for biomedical research due to its similarity to human physiology. However, the ease and lower costs associated with generating mutations in mice has lead to agreater reliance on genetically engineered mouse models despite the inability of many of these models to mimic human diseases. We outline a novel strategy that integrates our expertise in spermatogonial stem cells (SSCs) with a site-specific enzyme technology to increase efficiency of mutagenesis. We aim to establish an innovative transgenic rat service that will provide clients with a lower cost and more efficient alternative to the current genetically modified rat technology. Thus, if feasibility is demonstrated, this project would benefit many goals of public health by making the production of mutations in the rat that model human diseases readily accessible to the research community.

Principal Investigator:

Eric M. Ostertag
267-259-1086
OSTERTAG@transposagenbio.com

Business Contact:

Joseph C. Ruix
859-218-6567
jruiz@transposagenbio.com
Small Business Information at Submission:

TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
535 West Second Street Suite 10 Lexington, KY 40508

EIN/Tax ID: 186109298
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No